Review ArticleCardiac Regenerative Therapy Using Human Pluripotent Stem Cells for Heart Failure: A State-of-the-Art Review
Graphical abstract
Section snippets
Cardiac Differentiation of Human Pluripotent Stem Cells
Several researchers have reported cardiac differentiation of pluripotent stem cells (PSCs) to generate human CMs artificially. hPSCs can be induced to differentiate into CMs at various sites within the heart, including the atria, ventricles, sinus nodal pacemakers, and other structures. These cells show the same electrical activity characteristics demonstrated by human CMs.28 Protocols for the differentiation of hiPSCs into CMs have been established based on the development and differentiation
Elimination of Human Pluripotent Stem Cells and Purification of Cardiomyocytes
The current cardiac differentiation methods are highly efficient in producing hPSC-CMs. However, if all hPSCs do not differentiate into CMs (particularly if the rate of differentiation is not 100%), there is an increased risk of tumorigenesis secondary to contamination by non-CMs and undifferentiated cells at the time of transplantation. This is a considerable barrier to the realization of cardiac regenerative medicine. Therefore, safe transplantation without the risk of tumorigenesis
Strategy for Transplantation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes
A previous study investigating regenerative therapy with CM transplantation reported successful transplantation and grafting of hiPSC-CMs prepared from skin fibroblasts of patients with HF into rats’ hearts.52 Another study showed that human ESC (hESC)-derived CMs (hESC-CMs) transplanted into a guinea pig myocardial infarction model led to improved cardiac function and decreased ventricular arrhythmias.53 These results indicate the potential utility and feasibility of ESC- or iPSC-derived CMs
Arrhythmia After Transplantation of Human Pluripotent Stem Cell Derived-Cardiomyocytes
Arrhythmias and immune response-mediated transplant rejection are serious adverse events associated with CM transplantation. The development of arrhythmias in patients with severe HF who were injected with skeletal myoblasts has been reported.72 Connexin 43 and N-cadherin, which are essential to the establishment of electrophysiological connections between cardiomyocytes, are not expressed in myoblasts, and automatism in myoblasts73 can precipitate arrhythmias. Cardiomyocytes can establish
Future Perspectives
Technological advancements have provided effective strategies for the resolution of these issues and for further development of cardiac regeneration therapy. A clinical trial in which hPSC-CMs will be transplanted into patients with severe dilated cardiomyopathy is in progress. For post-transplantation arrhythmias and immune rejection, the optimal regimen of antiarrhythmic and immunosuppressive agents needs to be further validated. The dosage and quality of hPSC-CMs should also be optimized.
Lay Summary
Heart transplantation (HT) is the only radical treatment available for patients with end-stage heart failure. However, HT as a therapeutic option is limited by marked donor shortage. To overcome this difficulty, regenerative medicine using human-induced pluripotent stem cells (hiPSCs) has drawn increasing attention as an alternative to HT. HiPSC-CMs transplantation may improve cardiac function via paracrine effects and electrical coupling with the host myocardium. Recent technological advances
Disclosures
KF is a cofounder and CEO of Heartseed, Inc. ST is an advisor of Heartseed, Inc. ST, HK and KF own equity in Heartseed, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by Projects for Technological Development, Research Center Network for Realization of Regenerative Medicine by Japan, the Japan Society for the Promotion of Science (JSPS) KAKENHI 20K17129 and 22K08164 to YK, and KAKENHI 20H05744 to ST.
References (90)
- et al.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Lancet
(2010) - et al.
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
Lancet
(2020) - et al.
Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals
Lancet
(2018) - et al.
The impact of obesity on patients bridged to transplantation with continuous-flow left ventricular assist devices
JACC Heart Fail
(2016) - et al.
Increasing the United States heart transplant donor pool with donation after circulatory death
J Thorac Cardiovasc Surg
(2020) - et al.
The future of heart procurement with donation after circulatory death: current practice and opportunities for advancement
J Heart Lung Transplant
(2022) - et al.
Production of functional cardiomyocytes and cardiac tissue from human induced pluripotent stem cells for regenerative therapy
J Mol Cell Cardiol
(2022) - et al.
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Cell
(2006) - et al.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors
Cell
(2007) - et al.
Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies
J Card Fail
(2015)